Product Code: A00339
The global pediatric vaccine market accounted for $2,1371.73 million in 2021, and is expected to reach $ 3,6390.99 million by 2031, registering a CAGR of 5.4% from 2022 to 2031.
Pediatric vaccine is a biological preparation that is administered to produce acquired immunity in children. Administration of vaccines aids to enhance immune response against a specific pathogen. Pediatric vaccinations play a key role in sustaining children health across different countries; hence, they are used in various national disease-prevention strategies. Owing to the increased occurrence of both viral and bacterial infectious diseases, the demand for vaccines has grown over the past few years. Pediatric vaccinations are primarily provided to children of different ages, improving their immune system during their lives and ensuring defense against various forms of infectious diseases.
It is estimated that pediatric vaccine market is expected to experience significant market growth during the forecast period as there has been surge in adoption in several countries across the globe in the national immunization programs. In addition, rise in prevalence of pneumococcal, influenza, and meningococcal disease in several countries has led to upsurge in demand for vaccines, which further facilitate the growth of the market. However, stringent government regulations for the approval of new vaccines and recall of several products are expected to impede the market growth. In contrast, rise in demand in emerging markets, increase in R&D activities to develop new vaccines, and surge in healthcare spending are anticipated to provide significant growth opportunities for the pediatric vaccine market.
The pediatric vaccine market is segmented on the basis of type, technology, indication, and region. On the basis of type, the market is bifurcated into monovalent and multivalent. Depending on technology, it is classified into live attenuated vaccines, inactivated vaccines, toxoid vaccines, and subunit, recombinant, polysaccharide, and conjugate vaccines. By indication, it is classified into varicella, diphtheria, pertussis & tetanus, influenza, human papilloma virus, measles, mumps & rubella, meningococcal disease, pneumococcal disease, polio, rotavirus, and others.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The report provides a comprehensive analysis of the key players that operate in the global pediatric vaccine market. Key companies profiled in the report include Serum Institute of India Pvt. Ltd., Pfizer, Johnson & Johnson, AstraZeneca plc. GlaxoSmithKline plc., Sanofi Aventis, Merck & Co., Inc., Emergent BioSolutions Inc., CSL Limited, and Novavax, Inc.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global paediatric vaccine market analysis from 2021 to 2031 to identify the prevailing global paediatric vaccine market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the global paediatric vaccine market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global global paediatric vaccine market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Technology
- Live Attenuated Vaccines
- Inactivated Vaccines
- Toxoid Vaccines
- Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines
By Type
By Indication
- Varicella
- Measles, Mumps and Rubella
- Meningococcal Disease
- Pneumococcal Disease
- Polio
- Rotavirus
- Diphtheria, Pertussis and Tetanus
- Influenza
- Human Papilloma Virus
- Other Indications
By Region
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest Of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest Of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest Of LAMEA
- Key Market Players
- AstraZeneca Plc.
- CSL Limited
- Emergent BioSolutions Inc.
- GlaxoSmithKline plc.
- Johnson & Johnson
- Merck & Co., Inc.
- Novavax, Inc.
- Pfizer Inc.
- Sanofi Aventis
- Serum Institute of India Pvt. Ltd.
TABLE OF CONTENTS
CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter's five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Monovalent
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market share analysis by country
- 4.3 Multivalent
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market share analysis by country
CHAPTER 5: GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Live Attenuated Vaccines
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market share analysis by country
- 5.3 Inactivated Vaccines
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market share analysis by country
- 5.4 Toxoid Vaccines
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market share analysis by country
- 5.5 Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines
- 5.5.1 Key market trends, growth factors and opportunities
- 5.5.2 Market size and forecast, by region
- 5.5.3 Market share analysis by country
CHAPTER 6: GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Varicella
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market share analysis by country
- 6.3 Diphtheria, Pertussis and Tetanus
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market share analysis by country
- 6.4 Influenza
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market share analysis by country
- 6.5 Human Papilloma Virus
- 6.5.1 Key market trends, growth factors and opportunities
- 6.5.2 Market size and forecast, by region
- 6.5.3 Market share analysis by country
- 6.6 Measles, Mumps and Rubella
- 6.6.1 Key market trends, growth factors and opportunities
- 6.6.2 Market size and forecast, by region
- 6.6.3 Market share analysis by country
- 6.7 Meningococcal Disease
- 6.7.1 Key market trends, growth factors and opportunities
- 6.7.2 Market size and forecast, by region
- 6.7.3 Market share analysis by country
- 6.8 Pneumococcal Disease
- 6.8.1 Key market trends, growth factors and opportunities
- 6.8.2 Market size and forecast, by region
- 6.8.3 Market share analysis by country
- 6.9 Polio
- 6.9.1 Key market trends, growth factors and opportunities
- 6.9.2 Market size and forecast, by region
- 6.9.3 Market share analysis by country
- 7.0 Rotavirus
- 7.0.1 Key market trends, growth factors and opportunities
- 7.0.2 Market size and forecast, by region
- 7.0.3 Market share analysis by country
- 7.1 Other Indications
- 7.1.1 Key market trends, growth factors and opportunities
- 7.1.2 Market size and forecast, by region
- 7.1.3 Market share analysis by country
CHAPTER 7: GLOBAL PEDIATRIC VACCINES MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Type
- 7.2.3 North America Market size and forecast, by Technology
- 7.2.4 North America Market size and forecast, by Indication
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Key market trends, growth factors and opportunities
- 7.2.5.1.2 Market size and forecast, by Type
- 7.2.5.1.3 Market size and forecast, by Technology
- 7.2.5.1.4 Market size and forecast, by Indication
- 7.2.5.2 Canada
- 7.2.5.2.1 Key market trends, growth factors and opportunities
- 7.2.5.2.2 Market size and forecast, by Type
- 7.2.5.2.3 Market size and forecast, by Technology
- 7.2.5.2.4 Market size and forecast, by Indication
- 7.2.5.3 Mexico
- 7.2.5.3.1 Key market trends, growth factors and opportunities
- 7.2.5.3.2 Market size and forecast, by Type
- 7.2.5.3.3 Market size and forecast, by Technology
- 7.2.5.3.4 Market size and forecast, by Indication
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Type
- 7.3.3 Europe Market size and forecast, by Technology
- 7.3.4 Europe Market size and forecast, by Indication
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Key market trends, growth factors and opportunities
- 7.3.5.1.2 Market size and forecast, by Type
- 7.3.5.1.3 Market size and forecast, by Technology
- 7.3.5.1.4 Market size and forecast, by Indication
- 7.3.5.2 France
- 7.3.5.2.1 Key market trends, growth factors and opportunities
- 7.3.5.2.2 Market size and forecast, by Type
- 7.3.5.2.3 Market size and forecast, by Technology
- 7.3.5.2.4 Market size and forecast, by Indication
- 7.3.5.3 UK
- 7.3.5.3.1 Key market trends, growth factors and opportunities
- 7.3.5.3.2 Market size and forecast, by Type
- 7.3.5.3.3 Market size and forecast, by Technology
- 7.3.5.3.4 Market size and forecast, by Indication
- 7.3.5.4 Italy
- 7.3.5.4.1 Key market trends, growth factors and opportunities
- 7.3.5.4.2 Market size and forecast, by Type
- 7.3.5.4.3 Market size and forecast, by Technology
- 7.3.5.4.4 Market size and forecast, by Indication
- 7.3.5.5 Spain
- 7.3.5.5.1 Key market trends, growth factors and opportunities
- 7.3.5.5.2 Market size and forecast, by Type
- 7.3.5.5.3 Market size and forecast, by Technology
- 7.3.5.5.4 Market size and forecast, by Indication
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Key market trends, growth factors and opportunities
- 7.3.5.6.2 Market size and forecast, by Type
- 7.3.5.6.3 Market size and forecast, by Technology
- 7.3.5.6.4 Market size and forecast, by Indication
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Type
- 7.4.3 Asia-Pacific Market size and forecast, by Technology
- 7.4.4 Asia-Pacific Market size and forecast, by Indication
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 China
- 7.4.5.1.1 Key market trends, growth factors and opportunities
- 7.4.5.1.2 Market size and forecast, by Type
- 7.4.5.1.3 Market size and forecast, by Technology
- 7.4.5.1.4 Market size and forecast, by Indication
- 7.4.5.2 Japan
- 7.4.5.2.1 Key market trends, growth factors and opportunities
- 7.4.5.2.2 Market size and forecast, by Type
- 7.4.5.2.3 Market size and forecast, by Technology
- 7.4.5.2.4 Market size and forecast, by Indication
- 7.4.5.3 India
- 7.4.5.3.1 Key market trends, growth factors and opportunities
- 7.4.5.3.2 Market size and forecast, by Type
- 7.4.5.3.3 Market size and forecast, by Technology
- 7.4.5.3.4 Market size and forecast, by Indication
- 7.4.5.4 Australia
- 7.4.5.4.1 Key market trends, growth factors and opportunities
- 7.4.5.4.2 Market size and forecast, by Type
- 7.4.5.4.3 Market size and forecast, by Technology
- 7.4.5.4.4 Market size and forecast, by Indication
- 7.4.5.5 South Korea
- 7.4.5.5.1 Key market trends, growth factors and opportunities
- 7.4.5.5.2 Market size and forecast, by Type
- 7.4.5.5.3 Market size and forecast, by Technology
- 7.4.5.5.4 Market size and forecast, by Indication
- 7.4.5.6 Rest of Asia-Pacific
- 7.4.5.6.1 Key market trends, growth factors and opportunities
- 7.4.5.6.2 Market size and forecast, by Type
- 7.4.5.6.3 Market size and forecast, by Technology
- 7.4.5.6.4 Market size and forecast, by Indication
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Type
- 7.5.3 LAMEA Market size and forecast, by Technology
- 7.5.4 LAMEA Market size and forecast, by Indication
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Key market trends, growth factors and opportunities
- 7.5.5.1.2 Market size and forecast, by Type
- 7.5.5.1.3 Market size and forecast, by Technology
- 7.5.5.1.4 Market size and forecast, by Indication
- 7.5.5.2 Saudi Arabia
- 7.5.5.2.1 Key market trends, growth factors and opportunities
- 7.5.5.2.2 Market size and forecast, by Type
- 7.5.5.2.3 Market size and forecast, by Technology
- 7.5.5.2.4 Market size and forecast, by Indication
- 7.5.5.3 South Africa
- 7.5.5.3.1 Key market trends, growth factors and opportunities
- 7.5.5.3.2 Market size and forecast, by Type
- 7.5.5.3.3 Market size and forecast, by Technology
- 7.5.5.3.4 Market size and forecast, by Indication
- 7.5.5.4 Rest of LAMEA
- 7.5.5.4.1 Key market trends, growth factors and opportunities
- 7.5.5.4.2 Market size and forecast, by Type
- 7.5.5.4.3 Market size and forecast, by Technology
- 7.5.5.4.4 Market size and forecast, by Indication
CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
CHAPTER 9: COMPANY PROFILES
- 9.1 AstraZeneca Plc.
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 CSL Limited
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 Emergent BioSolutions Inc.
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 GlaxoSmithKline plc.
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 Johnson & Johnson
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 Merck & Co., Inc.
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 Novavax, Inc.
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 Pfizer Inc.
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 Sanofi Aventis
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 Serum Institute of India Pvt. Ltd.
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments